Novo Nordisk CEO on disappointing Rybelsus sales: Influenced by lockdown

Sales of diabetes tablet Rybelsus have been significantly lower than what analysts had predicted, according to Wednesday’s quarterly report from Novo Nordisk. CEO Lars Fruergaard Jørgensen thinks this is due to lockdowns.

Photo: Stine Bidstrup/ERH

In spite of GLP-1 sales increasing overall, Novo Nordisk's diabetes tablet Rybelsus sold for significantly less than what industry analysts had forecast for the first three months of the year.

Based on estimates gathered by Novo Nordisk from around 28 analysts before the publication of the report, Rybelsus was predicted to surpass DKK 1bn sales in this year's first quarter.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs